2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
2
Small Cell Lung Carcinoma
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Liposarcoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leiomyosarcoma
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Hemangiosarcoma
1
Dermatofibrosarcoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Breast Neoplasms
1
Interventions
Doxorubicin
25
Gemcitabine
16
Trabectedin
12
Ifosfamide
12
Radiotherapy
11
Docetaxel
10
Dacarbazine
8
pazopanib
7
Nivolumab
6
Specimen Handling
5
Biopsy
5
liposomal doxorubicin
4
Temozolomide
4
pembrolizumab
3
Sunitinib
3
Sorafenib
3
Radiation
3
Magnetic Resonance Spectroscopy
3
Filgrastim
3
rucaparib
2
pegfilgrastim
2
olaratumab
2
eribulin
2
durvalumab
2
cixutumumab
2
cemiplimab
2
brostallicin
2
belinostat
2
avelumab
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leiomyosarcoma
×
TTI-621
×
Clear all
NCT04996004
2024-12-11
TTI-621-03
Pfizer
Phase 2
Terminated
76 enrolled
53 charts